Analysts Issue Forecasts for AIM ImmunoTech Q2 Earnings

AIM ImmunoTech Inc. (NYSEAMERICAN:AIM) – Research analysts at Ascendiant Capital Markets lifted their Q2 2026 earnings estimates for shares of AIM ImmunoTech in a research note issued to investors on Sunday, May 31st. Ascendiant Capital Markets analyst E. Woo now expects that the company will post earnings per share of ($0.12) for the quarter, up from their prior forecast of ($0.37). Ascendiant Capital Markets has a “Buy” rating and a $9.00 price target on the stock. The consensus estimate for AIM ImmunoTech’s current full-year earnings is ($1.47) per share. Ascendiant Capital Markets also issued estimates for AIM ImmunoTech’s Q3 2026 earnings at ($0.12) EPS, Q4 2026 earnings at ($0.12) EPS, FY2026 earnings at ($0.63) EPS, Q1 2027 earnings at ($0.13) EPS, Q2 2027 earnings at ($0.13) EPS, Q3 2027 earnings at ($0.13) EPS, Q4 2027 earnings at ($0.13) EPS and FY2027 earnings at ($0.52) EPS.

Separately, Zacks Research lowered shares of AIM ImmunoTech from a “strong-buy” rating to a “hold” rating in a report on Friday, February 6th. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $9.00.

AIM ImmunoTech Trading Down 11.5%

Shares of AIM opened at $0.73 on Thursday. AIM ImmunoTech has a 1-year low of $0.21 and a 1-year high of $20.35. The company has a 50-day moving average of $0.50 and a 200 day moving average of $0.94. The firm has a market capitalization of $10.66 million, a price-to-earnings ratio of -0.11 and a beta of 1.18. The company has a debt-to-equity ratio of 0.10, a current ratio of 1.01 and a quick ratio of 1.01.

AIM ImmunoTech (NYSEAMERICAN:AIM) last announced its quarterly earnings data on Friday, May 15th. The company reported ($0.69) earnings per share for the quarter. The company had revenue of $0.02 million for the quarter.

Hedge Funds Weigh In On AIM ImmunoTech

Hedge funds and other institutional investors have recently modified their holdings of the business. DRW Securities LLC boosted its stake in shares of AIM ImmunoTech by 60.6% during the fourth quarter. DRW Securities LLC now owns 69,545 shares of the company’s stock valued at $79,000 after purchasing an additional 26,254 shares in the last quarter. Sabby Management LLC bought a new position in shares of AIM ImmunoTech during the third quarter valued at approximately $79,000. Finally, Corient Private Wealth LLC bought a new position in shares of AIM ImmunoTech during the second quarter valued at approximately $87,000. 12.02% of the stock is currently owned by institutional investors.

Key Headlines Impacting AIM ImmunoTech

Here are the key news stories impacting AIM ImmunoTech this week:

• Positive Sentiment: Ascendiant Capital Markets raised its earnings estimates for multiple future quarters and full-year periods, including FY2026 and FY2027, suggesting a more favorable outlook for AIM ImmunoTech’s loss trajectory and long-term earnings potential. AIM ImmunoTech analyst estimate revisions
• Positive Sentiment: The firm maintained a Buy rating and a $9.00 target price, which implies meaningful upside versus the stock’s current sub-$1 share price and may support investor optimism. AIM ImmunoTech analyst target price

AIM ImmunoTech Company Profile

AIM ImmunoTech is a clinical-stage biotechnology company focused on the development and commercialization of immune-modulating therapies for the treatment of viral infections and cancer. The company’s lead product candidate, Ampligen (rintatolimod), is a proprietary toll-like receptor 3 (TLR3) agonist that aims to enhance the body’s innate immune response. AIM ImmunoTech’s research and development efforts center on demonstrating the safety and efficacy of Ampligen as both a standalone therapy and in combination with other treatments.

In addition to its oncology and antiviral programs, the company is advancing clinical trials of Ampligen in patients with chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) and exploring potential applications for emerging viral threats.